<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607035</url>
  </required_header>
  <id_info>
    <org_study_id>J_Core_071226</org_study_id>
    <secondary_id>J_Core_071226_01</secondary_id>
    <nct_id>NCT00607035</nct_id>
  </id_info>
  <brief_title>The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)</brief_title>
  <official_title>The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jichi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jichi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate which combination therapy is more effective for&#xD;
      improving the blood pressure (BP) and reducing target organ damage in Japanese hypertensive&#xD;
      patients: Angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) or ARB&#xD;
      plus diuretics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Renin-angiotensin (RA) inhibitors have been demonstrated to be the most effective drugs for&#xD;
      reducing subclinical target organ damage in hypertensive patients. In several patients,&#xD;
      however, BP control is not sufficiently achieved by RA inhibitors alone, and a combination of&#xD;
      two drugs is frequently required. It is unclear whether a combination of RA inhibitors and&#xD;
      diuretics or CCB is more effective in reducing hypertensive target organ damage. Control of&#xD;
      central BP has been shown to be more effective than peripheral BP in predicting&#xD;
      cardiovascular events and target organ damage associated with hypertension. The J-CORE study&#xD;
      is active controlled, 2-arm parallel group comparison, prospective randomized open blinded&#xD;
      end-point (PROBE) design study. The ARB plus CCB combination therapy group is administered&#xD;
      olmesartan 20 mg/day and azelnidipine 16 mg/day and the ARB plus diuretics combination&#xD;
      therapy group receives olmesartan 20 mg/day and hydrochlorothiazide (HCTZ) 12.5 mg/day. At&#xD;
      least 100 patients will be enrolled in each group and the follow up duration will be 24&#xD;
      weeks. The primary endpoint is to compare the changes in the central aortic BP and the&#xD;
      ambulatory BP between the two groups. The secondary endpoint is to compare the changes in&#xD;
      office BP, home BP, and hypertensive target organ damage between the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in central BP and ambulatory BP</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in office BP and home BP.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hypertensive target organ damage. Clinical laboratory data.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil ＋Azelnidipine</intervention_name>
    <description>The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil + Hydrochlorothiazide</intervention_name>
    <description>The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.</description>
    <arm_group_label>H</arm_group_label>
    <other_name>arm H</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hypertensive outpatients aged 30 years or older, and less than 85 years (at the time&#xD;
             of informed consent), regardless of sex&#xD;
&#xD;
          -  Office systolic BP/diastolic BP &gt; 140/90 mmHg in a sitting position even if on&#xD;
             treatment with olmesartan 20 mg/day for 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary hypertension or malignant hypertension&#xD;
&#xD;
          -  History of myocardial infarction or cerebrovascular accidents within 6 months prior to&#xD;
             the screening&#xD;
&#xD;
          -  Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass&#xD;
             grafting (CABG) done within 6 months of screening or scheduled&#xD;
&#xD;
          -  Current treatment for congestive cardiac failure (New York Heart Association [NYHA]&#xD;
             functional class II or severer) or ejection fraction &lt;40%&#xD;
&#xD;
          -  Atrial fibrillation or atrial flutter&#xD;
&#xD;
          -  Renal dysfunction (serum creatinine ≥2 mg/dl)&#xD;
&#xD;
          -  Hepatic dysfunction (AST and/or ALT ≥100 IU/l)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuomi Kario</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jichi Medical University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jichi Medical University School of Medicine</name>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <last_update_submitted>November 19, 2008</last_update_submitted>
  <last_update_submitted_qc>November 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Kazuomi Kario</name_title>
    <organization>Jichi Medical University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

